"Following the review of the data of the 101 trial, the drug advanced to the Phase II 201 trial (NCT05424276). This is a 12-week, randomized, double-blind, multi-center, placebo-controlled, dose-ranging clinical trial of three IkT 148009 doses in patients with untreated Parkinson's disease."
------------------------------------
pretty encouraging video presentation. Good thing to keep an eye on. Thanks, JG
I thought that the trial had had to stop due to an fda hold notice
do you have a link for that? cause i can't find anything
Take a look at my posts.
thanks! and that's a real 'RED FLAG' isn't it? bummer
Why doesn't the article tell you why the hold was placed? I looked up reasons for holds on clinical trials. The article discusses possible reasons a trial could be put on hold:
fda.gov/drugs/investigation...
good point! good research! good post!
Inhibikase says that no adverse effects have been observed in past research so since they are supposed to supply a letter to the company within 30 days of the reason they have put the study on hold it seems like that should be available around Dec 7th
good post, thanks!
NAC symptomatic or disease modifying? Neuraly Announces Topline Results from Phase 2 Trial of NLY01 in Parkinson's Disease
Promising disease modifying therapies for PDTavapadon Lessens Motor Symptoms in Patients with Early-stage Parkinson’s, Phase 2 Trial FindsAromatic L‐Amino Acid Decarboxylase Gene Therapy Enhances Levodopa Response in Parkinson's Disease
